AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16741368
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (once daily SLIT)
Trial: 14703417
Drug: Aprotinin (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion of 0.5 x 10(6) KIU/h)
Trial: 8204123
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and subcutaneous heparin
Trial: 8204123
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and intravenous heparin
Trial: 1555479
Drug: Front-loaded, weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-loaded, weight-adjusted rt-PA and intravenous heparin
Trial: 1555479
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of streptokinase and rt-PA and intravenous heparin
Trial: 3921279
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (60 mg/24 hr)
Trial: 31007691
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (fish oil) 1500 mg/d
Trial: 26636393
Drug: Heparin management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin management
Trial: 22569432
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine (LC) supplementation, 250 mg tablets three times a day for eight weeks
Trial: 18823152
Drug: Testosterone modified
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone modified to match levels of younger men for 6 weeks; conversion of testosterone to estradiol blocked; production of testosterone blocked; placebo (no treatment)
Trial: 22016074
Drug: Shock therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock therapy
Trial: 8953409
Drug: Liposomal ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal ointment
Trial: 8953409
Drug: Plain drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain drug ointment
Trial: 8953409
Drug: Liposomal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal formulations with ultrasound
Trial: 9431834
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg
Trial: 2007326
Drug: Benazepril 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 2, 5, and 10 mg
Trial: 2007326
Drug: Open-label Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label Hydrochlorothiazide (25 mg/day) added to benazepril, hydrochlorothiazide, or placebo
Trial: 31420350
Drug: Reference erythropoiesis-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference erythropoiesis-stimulating agents
Trial: 21302117
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups with saline irrigation of 400 ml or more
Trial: 10481417
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected at a rate of 800 ml/hr after fentanyl 100 micrograms
Trial: 10481417
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected at a rate of 1 ml/s after fentanyl 100 micrograms
Trial: 1681840
Drug: Midazolam 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.08 mg kg‐1
Trial: 31648845
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy (ambrisentan and tadalafil)
Trial: 31648845
Drug: Pooled monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled monotherapy (ambrisentan or tadalafil)
Trial: 25950389
Drug: Preoperative subpterygial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Trial: 25950389
Drug: Intraoperative subpterygial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Trial: 24321802
Drug: SMART regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART regimen (budesonide-formoterol 200 μg and 6 μg per actuation, twice daily, plus as needed)
Trial: 17067979
Drug: Pycnogenol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily) for 8 weeks
Trial: 15526380
Drug: Selenium (1.156x10(‐7)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (1.156x10(‐7) mol/L) for 6 h in vitro or selenium-yeast (200 microg/d) for 8-12 wk
Trial: 15526380
Drug: Chronic hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic hepatitis patients (without selenium treatment)
Trial: 7011467
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dipyridamole in combination with 30 mg (0.5 mg/kg) of acetylsalicylic acid (ASA)
Trial: 7011467
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dipyridamole in combination with 50 mg (0.8 mg/kg) of acetylsalicylic acid (ASA)
Trial: 7011467
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dipyridamole in combination with 160 mg (2.6 mg/kg) of acetylsalicylic acid (ASA)
Trial: 7011467
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of dipyridamole in combination with 330 mg (5.7 mg/kg) of acetylsalicylic acid (ASA)
Trial: 7011467
Drug: Dipyridamole-ASA combinations
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole-ASA combinations with ASA doses of 0.5 to 0.8 mg/kg
Trial: 7011467
Drug: Dipyridamole-ASA combinations
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole-ASA combinations with ASA doses between 2.6 to 5.7 mg/kg
Trial: 31029154
Drug: TLP0-001 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLP0-001 in combination with S-1
Trial: 31029154
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with S-1
Trial: 29795561
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (not rhTM)
Trial: 19757018
Drug: Diaphragm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm and Replens lubricant gel
Trial: 6776577
Drug: Alcohol (0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.65 g/kg)
Trial: 21850690
Drug: Steroid-free immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free immunosuppression (arm 3)
Trial: 17960954
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for treatment-naive patients (lamivudine plus adefovir)
Trial: 15578509
Drug: Conventional percutaneous
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional percutaneous ethanol injection (PEI)
Trial: 15578509
Drug: Higher-dose percutaneous
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose percutaneous ethanol injection (PEI)
Trial: 2896126
Drug: Intravenous chlordesmethyldiazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chlordesmethyldiazepam (1 mg)
Trial: 2896126
Drug: Oral chlordesmethyldiazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlordesmethyldiazepam (tablets)
Trial: 2896126
Drug: Oral chlordesmethyldiazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlordesmethyldiazepam (drops)
Trial: 17996006
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 microg/kg IV before remifentanil infusion (Group Pre)
Trial: 17996006
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before remifentanil infusion (Group Post)
Trial: 10985648
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of rifampicin
Trial: 1511814
Drug: Immediate injection
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate injection sclerotherapy (group A)
Trial: 6396365
Drug: Routine continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine continuous i.v. heparin treatment (1000 units/h)
Trial: 24657991
Drug: Intervention Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Condition (IC): Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Trial: 24657991
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (UC): Printed patient education material and hypertension treatment guidelines for physicians.
Trial: 24657991
Drug: Intervention Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Condition (IC) in patients without diabetes mellitus: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Trial: 24657991
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (UC) in patients without diabetes mellitus: Printed patient education material and hypertension treatment guidelines for physicians.
Trial: 24657991
Drug: Intervention Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Condition (IC) in small-sized community health centers: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Trial: 24657991
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (UC) in small-sized community health centers: Printed patient education material and hypertension treatment guidelines for physicians.
Trial: 15543117
Drug: A combination
RxNorm normalized name: Enema combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of inhaled medical air and titrated intravenous midazolam
Trial: 15543117
Drug: A combination
RxNorm normalized name: Enema combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Trial: 15543117
Drug: A combination
RxNorm normalized name: Enema combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of an inhaled mixture of 0.3% sevoflurane and 40% nitrous oxide in oxygen with titrated intravenous midazolam
Trial: 11463590
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of deep inspiration during methacholine inhalation
Trial: 11463590
Drug: Allowed deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allowed deep inspiration during methacholine inhalation
Trial: 7994787
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg FARM by intravesical instillation every 2-4 weeks for 1 year
Trial: 7994787
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ADR by intravesical instillation every 2-4 weeks for 1 year
Trial: 7994787
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg FARM
Trial: 7994787
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ADR
Trial: 25916132
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment (proton pump inhibitors, antacids, prokinetics) in the main group (70 patients).
Trial: 25916132
Drug: Traditional drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional drug treatment (control group, 30 patients).
Trial: 25916132
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment in the main group (70 patients).
Trial: 17401693
Drug: Phosphate supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate supplement
Trial: 15321804
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg), vitamin B‐12 (0.4 mg)
Trial: 15321804
Drug: Vitamin B‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐6 (40 mg)
Trial: 15321804
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg) and vitamin B‐12 (0.4 mg) with additional folic acid (5 mg/d) for the first 2 weeks
Trial: 11254913
Drug: Combination hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination hormone replacement therapy (17beta-estradiol plus medroxyprogesterone acetate)
Trial: 11254913
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) alone (either 17beta-estradiol (1 mg) or conjugated equine estrogens (CEE) (0.625 mg))
Trial: 2196149
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg over 8 hr for 5 days or longer
Trial: 160237
Drug: Diazepam 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.16 mg kg‐1
Trial: 25492571
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration 0 ng/ml
Trial: 25492571
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration 1 ng/ml
Trial: 25492571
Drug: Remifentanil target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target concentration 2 ng/ml
Trial: 19602786
Drug: EE/CA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CA plus metformin (1,700 mg, cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Trial: 19602786
Drug: EE/CA (cyproterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CA (cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Trial: 14678372
Drug: Solifenacin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 20 mg
Trial: 9825973
Drug: Dexamethasone (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.25 mg kg(‐1) b.i.d. on d 1‐7; 0.12 mg kg(‐1) b.i.d. on d 8‐14; 0.05 mg kg(‐1) b.i.d. on d 15‐21; 0.02 mg kg(‐1) b.i.d. on d 22‐28)
Trial: 3881327
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid 750 mg daily
Trial: 656270
Drug: Clofibrate 2
RxNorm normalized name: clofibrate 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate 2 g daily
Trial: 26033312
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg·kg(‐1) (0.8 ml·kg(‐1))
Trial: 26033312
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1)
Trial: 26033312
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 2 μg·kg(‐1)
Trial: 26033312
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg·kg(‐1)
Trial: 26033312
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1) and 2 μg·kg(‐1)
Trial: 23868620
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic Acid (UDCA) 300-450 mg/d
Trial: 20469779
Drug: R +
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R + G; basal‐bolus regular and glargine insulin (R‐R‐R‐G)
Trial: 8901660
Drug: 650 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg/d aspirin
Trial: 6190548
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose cis-platinum, Oncovin (vincristine) and bleomycin (COB)
Trial: 29996127
Drug: Reduced fetuin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced fetuin‐A concentrations (g/L)
Trial: 28807912
Drug: MHAA4549A (3,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHAA4549A (3,600 mg)
Trial: 28807912
Drug: Oseltamivir (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (standard oral dose)
Trial: 26611872
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise training
Trial: 9076465
Drug: SR-alfuzosin 5
RxNorm normalized name: alfuzosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-alfuzosin 5 mg twice daily
Trial: 7690956
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (160 mg/day)
Trial: 3530572
Drug: Bevantolol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol, 150 mg
Trial: 3530572
Drug: Propranolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80 mg
Trial: 24902407
Drug: Oscillating-rotating power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillating-rotating power brush (Oral-B Professional Care 1000)
Trial: 19877824
Drug: GaAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAs laser therapy
Trial: 16152824
Drug: Ginkgolide nebulised
RxNorm normalized name: Ginkgolide A
DrugBank: Ginkgolide A (DB06743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgolide nebulised inhalation 10 mg/ml, twice daily, for 6 weeks
Trial: 16152824
Drug: Cromlyn sodium
RxNorm normalized name: Cromolyn Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromlyn sodium nebulised inhalation 20 mg/10 ml, twice daily, for 6 weeks
Trial: 16152824
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml, twice daily, for 4 weeks
Trial: 11052317
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy with omeprazole 20 mg once a day for three months
Trial: 11052317
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with omeprazole 20 mg once a day for three months
Trial: 8644692
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg elemental Ca/d as calcium citrate malate
Trial: 1725016
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 or 5 mg twice daily)
Trial: 6339292
Drug: Halometasone/triclosan cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halometasone/triclosan cream (0.05% halometasone and 1% triclosan)
Trial: 6339292
Drug: Betamethasone dipropionate/gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate/gentamicin sulphate cream (0.05% betamethasone dipropionate and 0.1% gentamicin sulphate)
Trial: 31056413
Drug: No anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-platelet therapy
Trial: 18405377
Drug: Mental practice-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental practice-based rehabilitation training (six-week, individually tailored therapy regime)
Trial: 12211224
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg bid)
Trial: 12211224
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg bid) and Diclofenac (75 mg bid)
Trial: 10761326
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral contraceptive pill (OCs)
Trial: 1466576
Drug: 2 gm
RxNorm normalized name: Algiderm 2 gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 gm dipirone plus 20 mg hyoscine N‐butylbromide
Trial: 334471
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg flurbiprofen
Trial: 6722830
Drug: 1 X
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days